Status: Recruiting

Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

Evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Paediatric B cell-related autoimmune diseases

Participants needed: 12

Trial details

Phase: Early Phase 1Age: 3+Biological sex: AllType: InterventionalSponsor: The Children's Hospital of Zhejiang University School of MedicineUpdated: Feb 3, 2026Locations: 1

Eligibility criteria

Informed consent: The participant (and guardian if the participant is a minor) m... [+38]

Subjects with known severe allergic reactions, hypersensitivity, contraindicatio... [+15]

Status: Recruiting

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.

Participants needed: 30

Trial details

Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Guangzhou Medical UniversityUpdated: Jun 25, 2024Locations: 2

Eligibility criteria

patients with advanced HCC,which express GPC3 protein. [+5]

Had accepted gene therapy before; [+9]

Status: Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.

Participants needed: 40

Trial details

Phase: Phase 2Age: 0-70Biological sex: AllType: InterventionalSponsor: KK Women's and Children's HospitalUpdated: Mar 9, 2023Locations: 2

Eligibility criteria

Relapsed or refractory B-cell ALL (all must be satisfied) [+9]

B-ALL with isolated extramedullary disease relapse [+12]

Status: Recruiting

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).

Participants needed: 20

Trial details

Phase: Phase 1Age: 6-65Biological sex: AllType: InterventionalSponsor: National University Hospital, SingaporeUpdated: Sep 14, 2021Locations: 1

Eligibility criteria

Minimum level of pulmonary reserve defined as Grade ≤ 1 dyspnoea and oxygen satu... [+5]

Failure to meet any of the inclusion criteria [+8]

Status: Recruiting

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).

Participants needed: 40

Trial details

Phase: Phase 1Age: 6-80Biological sex: AllType: InterventionalSponsor: National University Hospital, SingaporeUpdated: Sep 9, 2021Locations: 1

Eligibility criteria

Patients who are unable to tolerate standard chemotherapy due to significant tox... [+7]

Failure to meet any of the inclusion criteria. [+8]